Skip to content

Study · Case report or series · n = 1 · 2025

4 results

Development of Dysplastic Nevi in a Child with LEPR Deficiency Treated with Setmelanotide.

Nursoy H, Denkboy Öngen Y, Öztürk F, Balaban Adım Ş, Eren E

Journal of clinical research in pediatric endocrinology21 Aug 2025

PMID40836563 (opens in a new tab)DOI10.4274/jcrpe.galenos.2025.2025-5-14 (opens in a new tab)PepBankPUB-40836563
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A boy with LEPR deficiency developed skin hyperpigmentation shortly after starting setmelanotide.

    In plain wordsA boy with LEPR deficiency developed darker skin shortly after starting setmelanotide.

    Peptide
    Setmelanotide
    Outcome
    IncreaseSkin hyperpigmentation
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We present a 12-year-old boy with a homozygous LEPR mutation who experienced skin hyperpigmentation shortly after the initiation of setmelanotide treatment.
  2. 02HumanCase report or seriesSafety outcome

    A boy with LEPR deficiency developed gradually darker nevi by the third month of setmelanotide treatment.

    In plain wordsA boy's moles gradually darkened by the third month of setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    IncreaseNevus darkening
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    By the third month of treatment, gradual darkening of nevi was noted.
    1 context sentence
    Summary · context
    We present a 12-year-old boy with a homozygous LEPR mutation who experienced skin hyperpigmentation shortly after the initiation of setmelanotide treatment.
  3. 03HumanCase report or seriesSafety outcome

    At six-month follow-up during setmelanotide treatment, two excised nevi in a boy with LEPR deficiency both showed dysplasia.

    In plain wordsTwo moles removed from a boy receiving setmelanotide both showed abnormal tissue features at six-month follow-up.

    Peptide
    Setmelanotide
    Outcome
    Not applicableDysplastic nevi
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At six-month follow-up, two nevi were excised due to pigmentation changes, and histopathology revealed dysplastic features in both.
    1 context sentence
    Summary · context
    We present a 12-year-old boy with a homozygous LEPR mutation who experienced skin hyperpigmentation shortly after the initiation of setmelanotide treatment.
  4. 04HumanCase report or seriesSafety outcome

    Setmelanotide treatment was temporarily discontinued in the boy with LEPR deficiency and dysplastic nevi.

    In plain wordsDoctors temporarily stopped setmelanotide in the boy who developed abnormal moles.

    Peptide
    Setmelanotide
    Outcome
    Not applicableTemporary treatment discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Therapy was temporarily discontinued.
    2 context sentences
    Summary · context
    At six-month follow-up, two nevi were excised due to pigmentation changes, and histopathology revealed dysplastic features in both.
    Summary · context
    We present a 12-year-old boy with a homozygous LEPR mutation who experienced skin hyperpigmentation shortly after the initiation of setmelanotide treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.